blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News flashes

New version of the European Patent Register - SPC information for Unitary Patents.

2024-03-06

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP1802777

EP1802777 - ANTISENSE ANTIVIRAL COMPOUND AND METHOD FOR TREATING SSRNA VIRAL INFECTION [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  25.10.2013
Database last updated on 17.05.2024
Most recent event   Tooltip17.07.2015Lapse of the patent in a contracting state
New state(s): HU, LU		published on 19.08.2015  [2015/34]
Applicant(s)For all designated states
Sarepta Therapeutics, Inc.
3450 Monte Villa Parkway, Suite 101
Bothell, Washington 98021 / US
[2012/49]
Former [2007/27]For all designated states
AVI BioPharma, Inc.
Suite 200, 4575 S.W. Research Way
Corvallis, OR 97333 / US
Inventor(s)01 / IVERSEN, Patrick, L.
5902 N.W. Fair Oaks Place
Albany, OR 97330 / US
02 / STEIN, David, A.
2135 N.W. Evergreen Street
Corvallis, OR 97330 / US
 [2007/27]
Representative(s)Schiweck Weinzierl Koch Patentanwälte Partnerschaft mbB
Ganghoferstraße 68 B
80339 München / DE
[N/P]
Former [2011/41]Schiweck, Weinzierl & Koch
European Patent Attorneys Landsberger Straße 98
80339 München / DE
Former [2008/35]Vossius & Partner
Siebertstrasse 3
81675 München / DE
Former [2007/27]Vossius & Partner
Siebertstrasse 4
81675 München / DE
Application number, filing date05796604.615.09.2005
[2007/27]
WO2005US32815
Priority number, dateUS20040611063P16.09.2004         Original published format: US 611063 P
US2005022699514.09.2005         Original published format: US 226995
[2007/27]
Filing languageEN
Procedural languageEN
PublicationType: A2 Application without search report
No.:WO2006033933
Date:30.03.2006
Language:EN
[2006/13]
Type: A2 Application without search report 
No.:EP1802777
Date:04.07.2007
Language:EN
The application published by WIPO in one of the EPO official languages on 30.03.2006 takes the place of the publication of the European patent application.
[2007/27]
Type: B1 Patent specification 
No.:EP1802777
Date:19.12.2012
Language:EN
[2012/51]
Search report(s)International search report - published on:US27.07.2006
(Supplementary) European search report - dispatched on:EP13.01.2009
ClassificationIPC:C12N15/11
[2009/07]
CPC:
C12N15/1131 (EP,US); A61P31/12 (EP); A61P31/14 (EP);
C07K19/00 (US); C12N15/111 (EP,US); C12N2310/11 (EP,US);
C12N2310/314 (US); C12N2310/3233 (EP,US); C12N2310/3513 (US);
C12N2310/531 (US); C12N2320/11 (EP,US); C12N2770/00011 (EP,US);
C12N2770/10011 (US); C12N2770/12011 (US); C12N2770/16011 (US);
C12N2770/20011 (US); C12N2770/24011 (US); C12N2770/28011 (US);
C12N2770/32011 (US); C12N2770/36011 (US); Y02A50/30 (EP) (-)
Former IPC [2007/27]C12Q1/70
Designated contracting statesAT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   NL,   PL,   PT,   RO,   SE,   SI,   SK,   TR [2007/27]
Extension statesAL16.04.2007
BA16.04.2007
HR16.04.2007
MK16.04.2007
YU16.04.2007
TitleGerman:ANTIVIRALE ANTISENSE-VERBINDUNG UND VERFAHREN ZUR BEHANDLUNG EINER SSRNA-VIRUSINFEKTION[2007/27]
English:ANTISENSE ANTIVIRAL COMPOUND AND METHOD FOR TREATING SSRNA VIRAL INFECTION[2007/27]
French:COMPOSÉ ANTIVIRAL ANTISENS ET MÉTHODE DE TRAITEMENT D'UNE INFECTION VIRALE À ARNSS[2007/27]
Entry into regional phase16.04.2007National basic fee paid 
16.04.2007Search fee paid 
16.04.2007Designation fee(s) paid 
16.04.2007Examination fee paid 
Examination procedure16.04.2007Examination requested  [2007/27]
08.05.2009Despatch of a communication from the examining division (Time limit: M06)
18.11.2009Reply to a communication from the examining division
27.08.2010Despatch of a communication from the examining division (Time limit: M06)
08.04.2011Despatch of communication that the application is deemed to be withdrawn, reason: reply to the communication from the examining division not received in time
17.05.2011Reply to a communication from the examining division
23.09.2011Despatch of a communication from the examining division (Time limit: M06)
03.04.2012Reply to a communication from the examining division
12.07.2012Communication of intention to grant the patent
09.11.2012Fee for grant paid
09.11.2012Fee for publishing/printing paid
Divisional application(s)The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is  08.05.2009
Opposition(s)20.09.2013No opposition filed within time limit [2013/48]
Request for further processing for:The application is deemed to be withdrawn due to failure to reply to the examination report
17.05.2011Request for further processing filed
17.05.2011Full payment received (date of receipt of payment)
Request granted
30.05.2011Decision despatched
Fees paidRenewal fee
16.04.2007Renewal fee patent year 03
15.09.2008Renewal fee patent year 04
11.09.2009Renewal fee patent year 05
27.09.2010Renewal fee patent year 06
26.09.2011Renewal fee patent year 07
25.09.2012Renewal fee patent year 08
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipHU15.09.2005
AT19.12.2012
BE19.12.2012
CY19.12.2012
CZ19.12.2012
DK19.12.2012
EE19.12.2012
FI19.12.2012
IT19.12.2012
LT19.12.2012
LV19.12.2012
MC19.12.2012
PL19.12.2012
RO19.12.2012
SI19.12.2012
SK19.12.2012
TR19.12.2012
BG19.03.2013
GR20.03.2013
ES30.03.2013
IS19.04.2013
PT19.04.2013
LU15.09.2013
[2015/34]
Former [2015/32]AT19.12.2012
BE19.12.2012
CY19.12.2012
CZ19.12.2012
DK19.12.2012
EE19.12.2012
FI19.12.2012
IT19.12.2012
LT19.12.2012
LV19.12.2012
MC19.12.2012
PL19.12.2012
RO19.12.2012
SI19.12.2012
SK19.12.2012
TR19.12.2012
BG19.03.2013
GR20.03.2013
ES30.03.2013
IS19.04.2013
PT19.04.2013
Former [2015/30]AT19.12.2012
BE19.12.2012
CY19.12.2012
CZ19.12.2012
DK19.12.2012
EE19.12.2012
FI19.12.2012
IT19.12.2012
LT19.12.2012
LV19.12.2012
MC19.12.2012
PL19.12.2012
RO19.12.2012
SI19.12.2012
SK19.12.2012
BG19.03.2013
GR20.03.2013
ES30.03.2013
IS19.04.2013
PT19.04.2013
Former [2014/20]AT19.12.2012
BE19.12.2012
CZ19.12.2012
DK19.12.2012
EE19.12.2012
FI19.12.2012
IT19.12.2012
LT19.12.2012
LV19.12.2012
MC19.12.2012
PL19.12.2012
RO19.12.2012
SI19.12.2012
SK19.12.2012
BG19.03.2013
GR20.03.2013
ES30.03.2013
IS19.04.2013
PT19.04.2013
Former [2014/03]AT19.12.2012
BE19.12.2012
CZ19.12.2012
DK19.12.2012
EE19.12.2012
FI19.12.2012
IT19.12.2012
LT19.12.2012
LV19.12.2012
PL19.12.2012
RO19.12.2012
SI19.12.2012
SK19.12.2012
BG19.03.2013
GR20.03.2013
ES30.03.2013
IS19.04.2013
PT19.04.2013
Former [2013/48]AT19.12.2012
BE19.12.2012
CZ19.12.2012
DK19.12.2012
EE19.12.2012
FI19.12.2012
LT19.12.2012
LV19.12.2012
PL19.12.2012
RO19.12.2012
SI19.12.2012
SK19.12.2012
BG19.03.2013
GR20.03.2013
ES30.03.2013
IS19.04.2013
PT19.04.2013
Former [2013/40]AT19.12.2012
BE19.12.2012
CZ19.12.2012
EE19.12.2012
FI19.12.2012
LT19.12.2012
LV19.12.2012
PL19.12.2012
RO19.12.2012
SI19.12.2012
SK19.12.2012
BG19.03.2013
GR20.03.2013
ES30.03.2013
IS19.04.2013
PT19.04.2013
Former [2013/37]AT19.12.2012
BE19.12.2012
CZ19.12.2012
EE19.12.2012
FI19.12.2012
LT19.12.2012
LV19.12.2012
PL19.12.2012
RO19.12.2012
SI19.12.2012
SK19.12.2012
BG19.03.2013
GR20.03.2013
ES30.03.2013
IS19.04.2013
Former [2013/36]AT19.12.2012
BE19.12.2012
CZ19.12.2012
EE19.12.2012
FI19.12.2012
LT19.12.2012
LV19.12.2012
PL19.12.2012
SI19.12.2012
SK19.12.2012
BG19.03.2013
GR20.03.2013
ES30.03.2013
IS19.04.2013
Former [2013/35]BE19.12.2012
CZ19.12.2012
EE19.12.2012
FI19.12.2012
LT19.12.2012
LV19.12.2012
SI19.12.2012
SK19.12.2012
BG19.03.2013
GR20.03.2013
ES30.03.2013
IS19.04.2013
Former [2013/34]BE19.12.2012
FI19.12.2012
LT19.12.2012
LV19.12.2012
SI19.12.2012
BG19.03.2013
GR20.03.2013
ES30.03.2013
IS19.04.2013
Former [2013/33]BE19.12.2012
FI19.12.2012
LT19.12.2012
LV19.12.2012
SI19.12.2012
GR20.03.2013
ES30.03.2013
Former [2013/26]FI19.12.2012
LT19.12.2012
LV19.12.2012
SI19.12.2012
GR20.03.2013
ES30.03.2013
Former [2013/24]FI19.12.2012
LT19.12.2012
LV19.12.2012
GR20.03.2013
ES30.03.2013
Former [2013/23]FI19.12.2012
LT19.12.2012
LV19.12.2012
ES30.03.2013
Former [2013/22]FI19.12.2012
LT19.12.2012
ES30.03.2013
Former [2013/20]LT19.12.2012
Documents cited:Search[X]WO03033657  (AVI BIOPHARMA INC [US]) [X] 1-32 * see whole doc. esp. claims *;
 [PX]WO2005007805  (AVI BIOPHARMA INC [US], et al) [PX] 1-32 * see whole doc. esp. claims *;
 [PX]WO2005030800  (AVI BIOPHARMA INC [US], et al) [PX] 1-32 * see whole doc. esp. claims, p.41, p.3. *;
 [X]  - SMITH A W ET AL, "Antisense treatment of caliciviridae: an emerging disease agent of animals and humans", CURRENT OPINION IN MOLECULAR THERAPEUTICS, CURRENT DRUGS, LONDON, GB, (20020401), vol. 4, no. 2, ISSN 1464-8431, pages 177 - 184, XP002968098 [X] 1-32 * the whole document *
 [X]  - NEUMAN B W ET AL, "ANTISENSE MORPHOLINO-OLIGOMERS DIRECTED AGAINST THE 5' END OF THE GENOME INHIBIT CORONAVIRUS PROLIFERATION AND GROWTH", JOURNAL OF VIROLOGY, THE AMERICAN SOCIETY FOR MICROBIOLOGY, US, (20040601), vol. 48, no. 11, ISSN 0022-538X, pages 5891 - 5899, XP002999957 [X] 1-32 * see whole doc. esp. abstract *

DOI:   http://dx.doi.org/10.1128/JVI.78.11.5891-5899.2004
 [A]  - MOULTON H M ET AL, "CELLULAR UPTAKE OF ANTISENSE MORPHOLINO OLIGOMERS CONJUGATED TO ARGININE-RICH PEPTIDES", BIOCONJUGATE CHEMISTRY, ACS, WASHINGTON, DC, US, (20040101), vol. 15, no. 2, ISSN 1043-1802, pages 290 - 299, XP002999956 [A] * the whole document *

DOI:   http://dx.doi.org/10.1021/bc034221g
International search[YP]US2005176661  (VAILLANT ANDREW [CA], et al);
 [Y]  - SMITH ET AL., J. VIRAL HEPATITIS, (2004), vol. 11, pages 115 - 123, XP002999953

DOI:   http://dx.doi.org/10.1046/j.1365-2893.2003.00476.x
 [Y]  - WANG ET AL., ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, (2001), vol. 45, pages 1043 - 1052, XP002999954

DOI:   http://dx.doi.org/10.1128/AAC.45.4.1043-1052.2001
 [Y]  - FREIER, Antisene Drug Technology: Principles, Strategies, and Applications, (2001), vol. CHPT. 5, pages 107 - 118, XP001538820
 [Y]  - JAEGER ET AL., PROC. NATL. ACAD. SCI., (1989), vol. 86, pages 7706 - 7710, XP000953154

DOI:   http://dx.doi.org/10.1073/pnas.86.20.7706
 [Y]  - SIPRASHVILI ET AL., HUMAN GEN. THER., (2003), vol. 14, pages 1225 - 1233, XP002999955

DOI:   http://dx.doi.org/10.1089/104303403767740768
 [Y]  - MOULTON ET AL., BIOCONJUGATE CHEM., (2004), vol. 15, pages 290 - 299, XP002999956

DOI:   http://dx.doi.org/10.1021/bc034221g
 [Y]  - NEUMAN ET AL., J. VIROL., (2004), vol. 78, pages 5891 - 5899, XP002999957

DOI:   http://dx.doi.org/10.1128/JVI.78.11.5891-5899.2004
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.